- Flamel Technologies and SmithKline Beecham have terminated theircollaboration in the area of vaccine delivery. Flamel regained the rights to its Medusa technology for the oral, mucosal and parenteral delivery of vaccines. According to SB, it was primarily interested in oral and nasal formulations of vaccines, which would require further work, and concluded its involvement in the project.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze